Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Successful treatment of myeloma cast nephropathy using bortezomib-based chemotherapy plus selective plasma exchange.

Kawabe M, Yamamoto I, Katsuma A, Hayashi N, Komatsuzaki Y, Nakada Y, Shimizu A, Tanno Y, Ohkido I, Tsuboi N, Suzuki K, Shimada T, Ogasawara Y, Sugiyama K, Aiba K, Yokoo T.

CEN Case Rep. 2016 Nov;5(2):232-237. doi: 10.1007/s13730-016-0231-4. Epub 2016 Aug 11.

2.

Current Trends of Renal Impairment in Multiple Myeloma.

Yadav P, Cook M, Cockwell P.

Kidney Dis (Basel). 2016 Mar;1(4):241-57. doi: 10.1159/000442511. Epub 2016 Feb 3. Review.

3.

Non-Secretory Myeloma, Diagnosed on Renal Biopsy as Cast Nephropathy.

Grover S, Selhi PK, Sood N, Sandhu JS, Kaur H.

J Clin Diagn Res. 2016 Jun;10(6):ED04-5. doi: 10.7860/JCDR/2016/19060.7925. Epub 2016 Jun 1.

4.

Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment.

Sugihara H, Chihara D, Seike K, Fukumoto K, Fujisawaa M, Suehara Y, Nishida Y, Takeuchi M, Matsue K.

Blood Cancer J. 2014 Aug 1;4:e235. doi: 10.1038/bcj.2014.56.

5.

Case report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone.

Patibandla BK, Narra A, Alwassia AA, Bartley A, Sandhu GS, Rooney J, Black RM.

Case Rep Nephrol. 2014;2014:940171. doi: 10.1155/2014/940171. Epub 2014 Jun 19.

6.

Multiple myeloma and kidney disease.

Katagiri D, Noiri E, Hinoshita F.

ScientificWorldJournal. 2013 Oct 27;2013:487285. doi: 10.1155/2013/487285. eCollection 2013. Review.

7.

Principles of separation: indications and therapeutic targets for plasma exchange.

Williams ME, Balogun RA.

Clin J Am Soc Nephrol. 2014 Jan;9(1):181-90. doi: 10.2215/CJN.04680513. Epub 2013 Oct 31. Review.

8.

Kidney disease and multiple myeloma.

Heher EC, Rennke HG, Laubach JP, Richardson PG.

Clin J Am Soc Nephrol. 2013 Nov;8(11):2007-17. doi: 10.2215/CJN.12231212. Epub 2013 Jul 18. Review.

9.

Early Application of High Cut-Off Haemodialysis for de-Novo Myeloma Nephropathy is Associated with Long-Term Dialysis-Independency and Renal Recovery.

Khalafallah AA, Loi SW, Love S, Mohamed M, Mace R, Khalil R, Girgs M, Raj R, Mathew M.

Mediterr J Hematol Infect Dis. 2013;5(1):e2013007. doi: 10.4084/MJHID.2013.007. Epub 2013 Jan 2.

10.

Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases.

Leung N, Gertz M, Kyle RA, Fervenza FC, Irazabal MV, Eirin A, Kumar S, Cha SS, Rajkumar SV, Lacy MQ, Zeldenrust SR, Buadi FK, Hayman SR, Nasr SH, Sethi S, Ramirez-Alvarado M, Witzig TE, Herrmann SM, Dispenzieri A.

Clin J Am Soc Nephrol. 2012 Dec;7(12):1964-8. doi: 10.2215/CJN.11161111. Epub 2012 Sep 27.

11.

Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy.

Hutchison CA, Cockwell P, Cook M.

BMC Clin Pathol. 2012 Aug 9;12:12. doi: 10.1186/1472-6890-12-12.

12.

Differences in immunoglobulin light chain species found in urinary exosomes in light chain amyloidosis (Al).

Ramirez-Alvarado M, Ward CJ, Huang BQ, Gong X, Hogan MC, Madden BJ, Charlesworth MC, Leung N.

PLoS One. 2012;7(6):e38061. doi: 10.1371/journal.pone.0038061. Epub 2012 Jun 18.

13.

Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model.

Ying WZ, Allen CE, Curtis LM, Aaron KJ, Sanders PW.

J Clin Invest. 2012 May;122(5):1777-85. doi: 10.1172/JCI46490. Epub 2012 Apr 9.

14.

Treating myeloma cast nephropathy without treating myeloma.

Leung N.

J Clin Invest. 2012 May;122(5):1605-8. doi: 10.1172/JCI63248. Epub 2012 Apr 9.

15.

In vitro aggregation behavior of a non-amyloidogenic λ light chain dimer deriving from U266 multiple myeloma cells.

Arosio P, Owczarz M, Müller-Späth T, Rognoni P, Beeg M, Wu H, Salmona M, Morbidelli M.

PLoS One. 2012;7(3):e33372. doi: 10.1371/journal.pone.0033372. Epub 2012 Mar 14.

16.

Recent advances in the pathogenesis and management of cast nephropathy (myeloma kidney).

Stringer S, Basnayake K, Hutchison C, Cockwell P.

Bone Marrow Res. 2011;2011:493697. doi: 10.1155/2011/493697. Epub 2011 May 4.

17.

The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.

Hutchison CA, Batuman V, Behrens J, Bridoux F, Sirac C, Dispenzieri A, Herrera GA, Lachmann H, Sanders PW; International Kidney and Monoclonal Gammopathy Research Group.

Nat Rev Nephrol. 2011 Nov 1;8(1):43-51. doi: 10.1038/nrneph.2011.168. Review.

18.

Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.

Faiman BM, Mangan P, Spong J, Tariman JD; The International Myeloma Foundation Nurse Leadership Board.

Clin J Oncol Nurs. 2011 Aug;15 Suppl:66-76. doi: 10.1188/11.CJON.S1.66-76.

19.

Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S, Rajkumar SV, Kyle RA, Leung N.

J Am Soc Nephrol. 2011 Jun;22(6):1129-36. doi: 10.1681/ASN.2010080857. Epub 2011 Apr 21.

20.

Complete remission of lambda light chain myeloma presenting with acute renal failure following treatment with bortezomib and steroids.

Pavan M, Ashwini KA, Ravi R, Suratkal LH.

Indian J Nephrol. 2010 Apr;20(2):94-6. doi: 10.4103/0971-4065.65304.

Supplemental Content

Support Center